In addition to being an active hormone, testosterone further breaks down into these active hormones.

Selective serotonin reuptake inhibitors (SSRIs) such as Sertraline (Zoloft) are commonly used first-line treatments for major depressive disorder. These medications work by increasing serotonin availability in the central nervous system, improving mood and anxiety symptoms over time. Unlike acute symptom-relief medications, SSRIs require consistent daily use and a delayed onset of full therapeutic effect. Patient education is essential to set realistic expectations and improve adherence during the initial treatment period.

Rationale:
A. Red-green color blindness is not associated with Sertraline (Zoloft). SSRIs do not affect retinal cone function or visual color processing pathways. Visual disturbances are not a recognized class effect, and this reflects a misconception unrelated to SSRI pharmacology or safety profile.

B. SSRIs such as Sertraline (Zoloft) typically require 4–8 weeks to achieve maximum therapeutic effect because neurochemical and receptor adaptations in the brain take time. While some early improvement in sleep or anxiety may occur, full antidepressant effects are delayed. Educating patients about this timeline helps prevent premature discontinuation due to perceived lack of benefit.

C. Chest pain is not a common or expected adverse effect of Sertraline (Zoloft) and should not be managed with aspirin as a routine response. Chest pain should always be evaluated for potential cardiac or other serious causes rather than attributed to SSRI therapy.

D. Probiotics are not part of standard education for preventing diarrhea related to Sertraline (Zoloft). While mild gastrointestinal upset such as nausea or diarrhea may occur initially with SSRIs, these symptoms usually resolve over time without specific probiotic therapy. Management is typically supportive and focused on tolerance rather than routine supplementation.

Clozapine (Clozaril) is an atypical antipsychotic used for treatment-resistant schizophrenia when other antipsychotics have failed. It is highly effective in reducing psychotic symptoms, especially in refractory cases, but its use is limited by serious and potentially life-threatening adverse effects. Because of these risks, it requires strict hematologic monitoring and is only used under specialized prescribing programs. Its safety profile is the main reason it is not first-line therapy.

Rationale:
A. Clozapine is not reserved for refractory schizophrenia due to cost, even though it may be more expensive than other antipsychotics. The primary limitation to its use is safety, not financial factors. Clinical decision-making is based on risk of serious adverse effects rather than medication cost alone.

B. Clozapine does not primarily mask hypoglycemia symptoms. While some antipsychotics can affect metabolic regulation and increase the risk of diabetes, masking hypoglycemia is not a key reason for restricted use of Clozapine (Clozaril). The major concern is hematologic toxicity rather than glucose symptom masking.

C. QTc prolongation can occur with some antipsychotics, but it is not the most significant or defining risk that restricts use of Clozapine (Clozaril). While cardiac monitoring is important, other agents such as ziprasidone have more prominent QTc concerns. Clozapine’s restriction is primarily driven by hematologic toxicity.

D. Clozapine carries a risk of severe and potentially fatal agranulocytosis, which is a profound decrease in white blood cells that can lead to life-threatening infections. Because of this risk, patients require mandatory regular absolute neutrophil count (ANC) monitoring under strict protocols. This serious hematologic adverse effect is the main reason Clozapine (Clozaril) is reserved for treatment-resistant schizophrenia.